The crisis, he says, is fueled by fentanyl, historical trauma, and a lack of resources. That’s why he and other Lummi leaders ...
Hosted on MSN39m
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug NipocalimabHOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent publication in mAbs. The study showcases the drug’s high-affinity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback